EP2496256A4 - Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines - Google Patents

Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines

Info

Publication number
EP2496256A4
EP2496256A4 EP10828938.0A EP10828938A EP2496256A4 EP 2496256 A4 EP2496256 A4 EP 2496256A4 EP 10828938 A EP10828938 A EP 10828938A EP 2496256 A4 EP2496256 A4 EP 2496256A4
Authority
EP
European Patent Office
Prior art keywords
poxvirus
immunoconjugates
subunit
peptides
directed against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10828938.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2496256A2 (en
Inventor
Alice P Taylor
Boby Makabi-Panzu
David M Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Molecular Medicine and Immunology
Original Assignee
Center for Molecular Medicine and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed by Center for Molecular Medicine and Immunology filed Critical Center for Molecular Medicine and Immunology
Publication of EP2496256A2 publication Critical patent/EP2496256A2/en
Publication of EP2496256A4 publication Critical patent/EP2496256A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP10828938.0A 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines Withdrawn EP2496256A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25836909P 2009-11-05 2009-11-05
US25872909P 2009-11-06 2009-11-06
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US37805910P 2010-08-30 2010-08-30
PCT/US2010/054668 WO2011056721A2 (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines

Publications (2)

Publication Number Publication Date
EP2496256A2 EP2496256A2 (en) 2012-09-12
EP2496256A4 true EP2496256A4 (en) 2013-07-17

Family

ID=43970701

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10828938.0A Withdrawn EP2496256A4 (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines

Country Status (6)

Country Link
EP (1) EP2496256A4 (https=)
CN (1) CN102573902A (https=)
AU (1) AU2010315432A1 (https=)
CA (1) CA2776563A1 (https=)
IN (1) IN2012DN02692A (https=)
WO (1) WO2011056721A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20150238632A1 (en) * 2012-09-18 2015-08-27 University Of Washington Through Its Center For Commercialization Compositions and Methods for Delivery of Antigens to Plasmacytoid Dendritic Cells
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
FI3377103T4 (fi) 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
CN109172818B (zh) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 一种蛋白牛痘疫苗及其效力检测方法
CN109187982B (zh) * 2018-08-02 2021-06-04 浙江康佰裕生物科技有限公司 一种tlr类疫苗佐剂的筛选和鉴定方法
EP3870217A4 (en) * 2018-10-22 2022-08-31 Icellkealex Therapeutics LLC MUTANT VACCINIA VIRUSES AND USE THEREOF
CN111474339A (zh) * 2020-04-17 2020-07-31 浙江康佰裕生物科技有限公司 一种利用荧光标记痘病毒颗粒的方法及其应用
KR20230003122A (ko) * 2020-04-27 2023-01-05 제노비에 에이비 바이러스 비-비리온-통합 유래 에피토프에 대한 인간 백혈구 항원 클래스 i 제한 cd8 t-세포 반응을 프라이밍하기 위한 백신 조성물의 생성 방법

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (en) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Hiv fusion polypeptide
WO1999036507A1 (en) * 1998-01-15 1999-07-22 Genitrix, Llc Vaccine compositions and methods of modulating immune responses
US20010014327A1 (en) * 1995-06-07 2001-08-16 Naveen N Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
US20020040130A1 (en) * 2000-07-10 2002-04-04 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20030198595A1 (en) * 1998-06-22 2003-10-23 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2004094613A2 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
WO2006107786A2 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US20070086942A1 (en) * 2005-10-19 2007-04-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2007046893A2 (en) * 2005-10-19 2007-04-26 Ibc Pharmaceuticals, Inc. Methods for generating bioactive assemblies and uses thereof
US20070140966A1 (en) * 2005-10-19 2007-06-21 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007075270A2 (en) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007134037A2 (en) * 2006-05-15 2007-11-22 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
WO2009055653A1 (en) * 2007-10-26 2009-04-30 Ibc Pharmaceuticals, Inc. Pegylation by the dock and lock (dnl) technique
US20090191225A1 (en) * 2005-04-06 2009-07-30 Ibc Pharmaceuticals, Inc. Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities
US20090202487A1 (en) * 2005-04-06 2009-08-13 Ibc Pharmaceuticals, Inc. Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
WO2009126558A1 (en) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395422T1 (de) * 1995-06-07 2008-05-15 Sanofi Pasteur Ltd Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
US7312318B2 (en) 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
ES2665422T3 (es) * 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (en) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Hiv fusion polypeptide
US20010014327A1 (en) * 1995-06-07 2001-08-16 Naveen N Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
WO1999036507A1 (en) * 1998-01-15 1999-07-22 Genitrix, Llc Vaccine compositions and methods of modulating immune responses
US20030198595A1 (en) * 1998-06-22 2003-10-23 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US20020040130A1 (en) * 2000-07-10 2002-04-04 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US20030232420A1 (en) * 2002-05-03 2003-12-18 Andreas Braun Kinase anchor protein muteins, peptides thereof and related documents
WO2004094613A2 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
WO2006107786A2 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US20090191225A1 (en) * 2005-04-06 2009-07-30 Ibc Pharmaceuticals, Inc. Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities
US20090202487A1 (en) * 2005-04-06 2009-08-13 Ibc Pharmaceuticals, Inc. Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
US20070086942A1 (en) * 2005-10-19 2007-04-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2007046893A2 (en) * 2005-10-19 2007-04-26 Ibc Pharmaceuticals, Inc. Methods for generating bioactive assemblies and uses thereof
US20070140966A1 (en) * 2005-10-19 2007-06-21 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007075270A2 (en) * 2005-12-16 2007-07-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2007134037A2 (en) * 2006-05-15 2007-11-22 Immunomedics, Inc. Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
WO2009055653A1 (en) * 2007-10-26 2009-04-30 Ibc Pharmaceuticals, Inc. Pegylation by the dock and lock (dnl) technique
WO2009126558A1 (en) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. M. GOLDENBERG ET AL: "Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting", THE JOURNAL OF NUCLEAR MEDICINE, vol. 49, no. 1, 1 January 2008 (2008-01-01), pages 158 - 163, XP055028152, ISSN: 0161-5505, DOI: 10.2967/jnumed.107.046185 *
See also references of WO2011056721A2 *

Also Published As

Publication number Publication date
AU2010315432A1 (en) 2012-04-12
EP2496256A2 (en) 2012-09-12
CN102573902A (zh) 2012-07-11
WO2011056721A2 (en) 2011-05-12
IN2012DN02692A (https=) 2015-09-04
CA2776563A1 (en) 2011-05-12
WO2011056721A3 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
EP2496256A4 (en) Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
FR21C1040I1 (fr) Formulations d'anticorps anti-cd20
EP2629801A4 (en) SYNERGIC IMPACT BETWEEN AURISTATIN-BASED ANTIBODY-ACTIVE CONJUGATES AND INHIBITORS OF THE PI3K ACT MTOR SIGNAL PATH
EP2203470A4 (en) VACCINES AND VACCUMENT COMPONENTS FOR THE INHIBITION OF MICROBIAL CELLS
EP2244720A4 (en) POLYPEPTIDE VACCINE AND VACCINE STRATEGY AGAINST MYCOBACTERIUM
IL200551A0 (en) Solid pharmaceutical and vaccine dose
SI2299971T1 (sl) Trdne farmacevtske formulacije, ki obsegajo BIBW 2992
EP2449114A4 (en) NEW LIPID FORMULATIONS FOR THE DELIVERY OF THERAPY AGENTS IN SOLID TUMORS
ZA201101477B (en) Co-crystals and pharmaceutical formulations comprising the same
EP2456471A4 (en) IRON-BASED PREPARATION FOR USE IN PHARMACEUTICAL PREPARATION AND PREPARATION METHOD THEREOF
LT2868315T (lt) Patobulintos kompozicijos ir liofilizacijos būdai bei gauti liofilizatai
IL187511A0 (en) Lipases for pharmaceutical use
EP2155859A4 (en) FORMULATIONS AND METHODS FOR CULTIVATING EMBRYONIC STEM CELLS
EP2303912A4 (en) CDCA1-EPITOP-PEPTIDES AND VACCINES CONTAINING THEM
HUE037105T2 (hu) Eljárások és készítmények tumorok megsemmisítésére
EP2449102A4 (en) ARGINASE FORMULATIONS AND METHODS
IL184735A0 (en) Pharmaceutical formulations and methods of use
IL208370A0 (en) Improved formulations for poorly permeable active pharmaceutical ingredients
FR18C1032I2 (fr) Anticorps anti-fgf23 et composition pharmaceutique le comprenant
EP2429577A4 (en) NEW HUMAN ROTAVIRENSTÄMME AND VACCINES
EP2393496A4 (en) IMPROVED VACCINES AGAINST HUMAN PAPILLOMA VIRUS AND METHOD FOR THEIR USE
EP2507256A4 (en) IMP-3 OLIGOPEPTIDES AND VACCINES THEREWITH
EP2134361A4 (en) Compositions and methods for increasing immunogenicity of glycoprotein vaccines
EP2222693A4 (en) MUTANTS OF LYSINDECARBOXYLASE, VACCINES AGAINST PERIODONTITIS AND METHOD OF USE
EP2220228A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE ADMINISTRATION OF NUCLEIC ACIDS IN CELLS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120601

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130619

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/56 20060101ALI20130613BHEP

Ipc: C07K 16/28 20060101ALI20130613BHEP

Ipc: A61K 47/48 20060101ALI20130613BHEP

Ipc: C07K 14/52 20060101ALI20130613BHEP

Ipc: A61P 35/00 20060101ALI20130613BHEP

Ipc: C07K 16/46 20060101AFI20130613BHEP

Ipc: C07K 16/24 20060101ALI20130613BHEP

Ipc: C07K 16/30 20060101ALI20130613BHEP

Ipc: C07K 16/44 20060101ALI20130613BHEP

Ipc: A61K 39/395 20060101ALI20130613BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20150401